1. Scrip
  2. >>Business

Lilly Faces India IP Challenges From Natco For Verzenio, Olumiant

 
• By Anju Ghangurde

Lilly’s anticancer abemaciclib and rheumatoid arthritis drug baricitinib, which has received a US EUA for COVID-19, have become targets of challenger Natco in India. The US giant says it's working closely with India’s health ministry to ensure access to patients who need its innovative therapies, amid indications Natco may be weighing plans to seek a voluntary license for baricitinib.

Intellectual property law
Lilly Will Need To Fend Off Challenge To Some Products In India • Source: Shutterstock

Eli Lilly and Company is at loggerheads with Natco Pharma Limited in India over intellectual property rights issues pertaining to the US firm’s breast cancer drug abemaciclib, while its JAK inhibitor baricitinib (sold as Olumiant) is also on the challenger’s radar.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip